The Effect of Perioperative Results on Mortality in Coronary Artery Bypass Surgery
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Feb 2, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effect of various risk factors on the survival of patients undergoing coronary artery bypass grafting (CABG), a common heart surgery often needed by older adults with other health issues. The aim is to identify which patients are at higher risk of complications or death after surgery by using a unique method called fuzzy logic. This method helps doctors understand and predict outcomes even when there is uncertain or incomplete information. The researchers will look at records of patients who had CABG surgery at Istanbul University-Cerrahpaşa between January 2020 and July 2024, focusing on both major and minor risk factors like diabetes, age, and smoking.
To participate in this study, patients must be 18 years or older and have undergone isolated coronary artery bypass surgery during the designated time. Those who had other types of surgeries will not be included. If you or a family member is eligible, you can expect that your medical records will be reviewed to help develop a risk classification model that could improve patient care and reduce complications after surgery. This research aims to enhance understanding of how different factors affect recovery and survival, potentially leading to better outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All isolated coronary artery bypass surgery between January 1, 2020 and July 31, 2024 at IUC Cardiology Institute hospital
- Exclusion Criteria:
- • All surgical procedures other than isolated coronary artery bypass surgery and patients under the age of 18 were excluded
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Trial Officials
Kerem Erkalp
Study Chair
Istanbul University - Cerrahpasa
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported